{"id":13401,"date":"2025-10-06T09:00:00","date_gmt":"2025-10-06T13:00:00","guid":{"rendered":"https:\/\/clario.com\/?post_type=newsroom&#038;p=13401"},"modified":"2025-10-03T16:44:31","modified_gmt":"2025-10-03T20:44:31","slug":"clario-and-the-university-of-oxfords-neurometrology-lab-advance-parkinsons-disease-research-with-the-opal-wearable-sensor-system","status":"publish","type":"newsroom","link":"https:\/\/clario.com\/about\/newsroom\/clario-and-the-university-of-oxfords-neurometrology-lab-advance-parkinsons-disease-research-with-the-opal-wearable-sensor-system\/","title":{"rendered":"Clario and the University of Oxford\u2019s NeuroMetrology Lab Advance Parkinson\u2019s Disease Research with the Opal\u00ae Wearable Sensor System"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li><em><strong>Clario partners with the University of Oxford\u2019s NeuroMetrology Lab<\/strong> to transform Parkinson\u2019s disease research with the Opal\u00ae wearable sensor system.&nbsp;<\/em><\/li>\n\n\n\n<li><em><strong>Partnership to advance clinical trial endpoints<\/strong> by improving identification of disease progression and movement-based endpoints.&nbsp;<\/em><\/li>\n\n\n\n<li><em>Digital endpoints of gait and balance combined with machine learning enable <strong>earlier detection of motor symptom progression.<\/strong>&nbsp;<\/em><\/li>\n\n\n\n<li><em><strong>Opal sensors can predict the risk of falls in Parkinson\u2019s patients<\/strong> with up to 92% accuracy two years in advance and 78% accuracy five years in advance.&nbsp;<\/em><\/li>\n<\/ul>\n\n\n\n<p>PHILADELPHIA \u2013 October 6, 2025 \u2013&nbsp;Clario, a leading provider of endpoint data solutions for clinical trials, today announced the enrollment of the first participant in its collaboration with the University of Oxford\u2019s NeuroMetrology Lab, led by Professor Chrystalina Antoniades. The partnership is focused on advancing the use of Clario\u2019s Opal\u00ae wearable sensor system to enhance Parkinson\u2019s disease (PD) research by enabling more precise measurement of motor symptoms and disease progression.&nbsp;<\/p>\n\n\n\n<p>The Opal\u00ae wearable sensor collects detailed, objective movement data through single- or multi-sensor setups, enabling the detection of subtle but meaningful changes in gait, balance, and mobility with a level of precision that surpasses traditional assessment methods. The <a href=\"https:\/\/www.nytimes.com\/2023\/10\/15\/health\/wearables-parkinsons-technology.html\" target=\"_blank\" rel=\"noreferrer noopener\">NeuroMetrology Lab\u2019s groundbreaking work<\/a>, powered by Opal\u2019s cutting-edge movement analysis capabilities, improves monitoring of disease progression and predicts adverse events such as falls, which represent a significant cause of disability and reduced quality of life in PD patients.&nbsp;<\/p>\n\n\n\n<p>Findings from Professor Antoniades&#8217; team demonstrate the high potential of movement analysis in PD research and pave the way for predictive and preventive healthcare. In a <a href=\"https:\/\/www.nature.com\/articles\/s41746-024-01311-5\" target=\"_blank\" rel=\"noreferrer noopener\">recent study<\/a>, a 3-minute in-office assessment predicted fall risk for Parkinson\u2019s patients with 84\u201392% accuracy up to two years in advance and 78% accuracy up to five years in advance. These predictive capabilities may change how the disease is managed and provide greater opportunity to evaluate therapeutic efficacy in clinical studies.&nbsp;<\/p>\n\n\n\n<p>\u201cOur collaboration with Professor Antoniades and her team is an exciting step forward in Parkinson\u2019s research,\u201d said Ellen Street, Executive Vice President and General Manager, Digital Physiology at Clario. \u201cThe team\u2019s research combined with the unique capabilities of the Opal device can improve monitoring of disease progression and enable a greater ability to understand the effect of a drug candidate in Parkinson\u2019s patients. It perfectly embodies Clario\u2019s mission to transform lives by unlocking better evidence.\u201d&nbsp;<\/p>\n\n\n\n<p>&#8220;We are excited to partner with Clario to enhance Parkinson\u2019s research using Opal\u2019s advanced movement analysis,\u201d said Professor Antoniades. \u201cThis collaboration will refine predictive models for fall risk and disease progression, improving patient outcomes. There is a crucial need for regulatory-approved digital movement endpoints in clinical trials to assess Parkinson\u2019s therapies accurately. Integrating validated, objective measures into drug development will enable precise evaluation and accelerate optimized treatments for patients.&#8221;&nbsp;<\/p>\n\n\n\n<p>This phase of the collaboration between Clario and the NeuroMetrology Lab will determine the usability and effectiveness of Opal data collected in remote settings via prescribed tasks in the home and real-world passive mobility monitoring, <a href=\"https:\/\/clario.com\/about\/newsroom\/clario-joins-forces-with-mobilise-d-to-advance-digital-mobility-outcomes-in-clinical-trials\/\">powered by Mobilise-D Digital Mobility Outcomes that Clario now offers.<\/a><\/p>\n\n\n\n<p>To learn more about Clario and its wearable sensor technologies, please visit <a href=\"https:\/\/clario.com\/solutions\/precision-motion\/\" target=\"_blank\" rel=\"noreferrer noopener\">Clario.com<\/a>.&nbsp;<\/p>\n\n\n\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<hr class=\"wp-block-separator has-text-color has-grey-color has-alpha-channel-opacity has-grey-background-color has-background\"\/>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-clario\">About Clario<\/h3>\n\n\n\n<p>Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac solutions, medical imaging, precision motion, and respiratory endpoints.\u202f&nbsp;<\/p>\n\n\n\n<p>For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported over 30,000 clinical trial opportunities in more than 100 countries. Our global team of science, technology, and operational experts have supported over 70% of FDA and EMA new drug approvals since 2015.&nbsp;<\/p>\n\n\n\n<p>For more information, go to <a href=\"https:\/\/clario.com\/\">Clario.com<\/a> or follow us on <a href=\"https:\/\/www.linkedin.com\/company\/clario-inc\" target=\"_blank\" rel=\"noreferrer noopener\">LinkedIn<\/a>.&nbsp;<\/p>\n\n\n\n<p><strong>Media Contact:<\/strong><br>media@clario.com<\/p>\n<\/div><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading mt-3\" id=\"h-about-university-of-oxford-s-neurometrology-lab\">About University of Oxford\u2019s NeuroMetrology Lab<\/h3>\n\n\n\n<p>The NeuroMetrology Lab at the University of Oxford, directed by Professor Chrystalina Antoniades, is dedicated to developing objective, quantitative tools to measure neurological function. By combining cutting-edge sensor technology, neurophysiology, and clinical neuroscience, the lab aims to improve the detection, monitoring, and treatment of movement disorders such as Parkinson\u2019s disease. Its interdisciplinary approach bridges academic research, clinical practice, and industry collaboration to accelerate the translation of scientific discoveries into real-world patient benefit.\u00a0<\/p>\n\n\n\n<p><a href=\"https:\/\/www.oxquip.co.uk\">www.oxquip.co.uk<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.linkedin.com\/company\/neurometrology-lab\">www.linkedin.com\/company\/neurometrology-lab<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-the-nuffield-department-of-clinical-neurosciences\">About the Nuffield Department of Clinical Neurosciences\u00a0<\/h3>\n\n\n\n<p><a href=\"http:\/\/www.ndcn.ox.ac.uk\/\" target=\"_blank\" rel=\"noreferrer noopener\">www.ndcn.ox.ac.uk<\/a>&nbsp;&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-oxford-university\">About Oxford University\u00a0<\/h3>\n\n\n\n<p><a href=\"file:\/\/\/C:\/Users\/sonia.ortner\/AppData\/Local\/Microsoft\/Olk\/Attachments\/ooa-e175db4d-16c8-45cf-9671-0c4a85b72c5c\/875ee3e96d531a127124ba3192c13fd98d96c3bf2cd2cc5eb6f8923b95a8d538\/www.ox.ac.uk\" target=\"_blank\" rel=\"noreferrer noopener\">www.ox.ac.uk<\/a>&nbsp;<\/p>\n\n\n\n<p><\/p>\n","protected":false},"featured_media":0,"template":"","tags":[342,102],"solution_areas":[343],"therapeutic_area":[36],"class_list":["post-13401","newsroom","type-newsroom","status-publish","hentry","tag-opal","tag-press-release"],"acf":[],"cp_meta_data":{"_edit_lock":["1759524812:7"],"_oembed_ef06f3e2e770020aaf086439ad97ce7a":["{{unknown}}"],"_edit_last":["7"],"media_coverage_logo":[""],"_media_coverage_logo":["field_62c529f1ff80c"],"media_coverage_color_logo":[""],"_media_coverage_color_logo":["field_630f051a114db"],"page_title":[""],"_page_title":["field_615dbd9cfca50"],"display_prefooter":["hide"],"_display_prefooter":["field_61641783f0f7c"],"persistent_cta":["hide"],"_persistent_cta":["field_6375dc7c0b25c"],"show_popup":["0"],"_show_popup":["field_62b1aec56dcb5"],"_ame_cpe_post_policy":["{\"accessProtection\":{\"active\":\"replace\"}}"],"_yoast_wpseo_content_score":["30"],"_yoast_wpseo_focuskeywords":[""],"_yoast_wpseo_keywordsynonyms":[""],"_yoast_wpseo_estimated-reading-time-minutes":["4"],"_yoast_indexnow_last_ping":["1759755610"]},"_links":{"self":[{"href":"https:\/\/clario.com\/wp-json\/wp\/v2\/newsroom\/13401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clario.com\/wp-json\/wp\/v2\/newsroom"}],"about":[{"href":"https:\/\/clario.com\/wp-json\/wp\/v2\/types\/newsroom"}],"version-history":[{"count":0,"href":"https:\/\/clario.com\/wp-json\/wp\/v2\/newsroom\/13401\/revisions"}],"wp:attachment":[{"href":"https:\/\/clario.com\/wp-json\/wp\/v2\/media?parent=13401"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clario.com\/wp-json\/wp\/v2\/tags?post=13401"},{"taxonomy":"solution_areas","embeddable":true,"href":"https:\/\/clario.com\/wp-json\/wp\/v2\/solution_areas?post=13401"},{"taxonomy":"therapeutic_area","embeddable":true,"href":"https:\/\/clario.com\/wp-json\/wp\/v2\/therapeutic_area?post=13401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}